Systemic Brain Delivery of Antisense Oligonucleotides across the Blood–Brain Barrier with a Glucose‐Coated Polymeric Nanocarrier

Current antisense oligonucleotide (ASO) therapies for the treatment of central nervous system (CNS) disorders are performed through invasive administration, thereby placing a major burden on patients. To alleviate this burden, we herein report systemic ASO delivery to the brain by crossing the blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Hyun Su, Kim, Hyun Jin, Naito, Mitsuru, Ogura, Satomi, Toh, Kazuko, Hayashi, Kotaro, Kim, Beob Soo, Fukushima, Shigeto, Anraku, Yasutaka, Miyata, Kanjiro, Kataoka, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317551/
https://www.ncbi.nlm.nih.gov/pubmed/31995252
http://dx.doi.org/10.1002/anie.201914751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317551/
https://www.ncbi.nlm.nih.gov/pubmed/31995252
http://dx.doi.org/10.1002/anie.201914751

Ejemplares similares